PhRMA Sues Trump Administration Over Most-Favored-Nation Drug Pricing Policy
The Pharmaceutical Research and Manufacturers of America (PhRMA) has filed a lawsuit against the Trump administration over its most-favored-nation (MFN) drug pricing policy. The MFN rule aims to reduce U.S. prescription drug costs by aligning them with prices in other developed countries, which are typically lower than those in the United States. The pharmaceutical industry argues that this policy unfairly limits their ability to set prices and could undermine innovation funding for new drugs. PhRMA represents major pharmaceutical companies and has long opposed government efforts to regulate prescription drug pricing more aggressively. This legal challenge highlights ongoing tensions between policymakers seeking to lower healthcare costs and the pharmaceutical sector, which claims such measures threaten investment in research and development.
Topics: drug pricing policy government regulation pharmaceutical industry